German multinational in pharma and life sciences
The nationwide settlement has been approved, covering current and future Roundup users who have or later develop non-Hodgkin lymphoma. Payouts vary by use and diagnosis, with average ranges reported; attorneys’ fees are included. The decision comes as Bayer faces ongoing litigation and a Supreme Court ruling that limits state-court claims.